Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2021-04-28 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific type of market announcement. Since this is a general regulatory announcement disseminated via the RNS system and does not fit into the more specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (SHA), it falls best under the general Regulatory Filings category (RNS). The document length is short (1931 chars), but it is the primary content itself, not an announcement *about* another report, so the RPA rule does not strictly apply here, although RNS is the most appropriate fit for this type of market notice.
2021-04-28 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1914 characters) and contains the header 'RNS Number : 9623W'. It announces a 'Price Monitoring Extension' related to trading rules on the London Stock Exchange, stating that the auction call period has been extended. It explicitly mentions that the information is provided by RNS, the news service of the London Stock Exchange, which is approved by the Financial Conduct Authority (FCA) to act as a Primary Information Provider. This is a general regulatory announcement that does not fit into specific financial reporting categories like 10-K, ER, or IR. Therefore, it falls under the general regulatory announcement category.
2021-04-28 English
Final Results
Earnings Release Classification · 99% confidence The document is titled 'Preliminary Results for the year ending 31 December 2020' and contains detailed financial highlights (Revenues, Operating loss, Cash balances) and operational updates for the full fiscal year. This strongly indicates it is an Annual Report or a document summarizing annual results. However, the document is issued via RNS (Regulatory News Service) and is explicitly labeled as 'Preliminary Results'. Preliminary results announcements, especially when issued via RNS, are typically classified as Earnings Releases (ER) if they are brief highlights, or Interim/Quarterly Reports (IR) if they cover a shorter period. Since this covers the full year but is presented as a preliminary announcement preceding the full audited 10-K, and it contains significant financial data, it aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed Earnings Release/Interim Report. Given the context of UK/AIM reporting, 'Preliminary Results' often serve as the precursor to the full 10-K filing. Since it contains comprehensive financial figures for the year, it is more substantial than a typical ER. However, the structure (RNS announcement format, 'Preliminary Results' title) suggests it is the initial public release of the annual figures, which is often categorized as an Earnings Release (ER) or, if comprehensive enough, sometimes treated as a substitute for the full 10-K in some databases, but the definition for 10-K specifies 'Official yearly report covering company activity and full financial performance.' This document is a summary of that performance. Since it covers the full year and provides detailed financial metrics, it is closest to the content of an Annual Report (10-K), but the format (RNS announcement) suggests it might be an Earnings Release (ER) or a Regulatory Filing (RNS). Given the depth of financial data provided (Revenues, Loss, Cash balances for the full year), it surpasses a typical brief ER. In many regulatory contexts, preliminary annual results are treated as the initial disclosure of the annual performance, which is often captured by ER. However, because it covers the entire year and is very long (over 100k characters), it functions as the primary annual disclosure before the formal 10-K filing. I will classify it as an Earnings Release (ER) because it is explicitly titled 'Preliminary Results' and disseminated via RNS, fitting the pattern of an initial results announcement, even if comprehensive. FY 2020
2021-04-22 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 0382W' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action announcement (like DIV or CAP). Since it is a direct, time-sensitive announcement distributed via the RNS system and does not fit any other specific category (like DIRS, MANG, or DIV), it falls best under the general regulatory announcement category, RNS.
2021-04-20 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1914 characters) and contains the header 'RNS Number : 0369W' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security's auction call period. This is a short, specific regulatory update that does not fit the criteria for a full report (10-K, IR, ER) or a specific corporate action like dividend or management change. Given the explicit reference to RNS and the nature of a brief, immediate market update, the most appropriate classification is the general regulatory announcement category.
2021-04-20 English
Clinical validation of AffiDX Lateral Flow Test
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated April 20, 2021. It announces positive clinical validation data for a SARS-CoV-2 antigen test and discusses next steps like CE marking and commercial launch. The presence of the RNS header, the announcement format, and the explicit mention of RNS as the provider at the end strongly indicate this is a regulatory news service announcement. Since the content is a specific operational/product update that doesn't fit neatly into ER, IR, CAP, or LTR, and it is clearly distributed via the official regulatory news service (RNS), the most appropriate classification is Regulatory Filings (RNS). The document length (9396 chars) is substantial enough that it is not merely an announcement *about* a report, but the report/update itself, distributed via RNS.
2021-04-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.